New Nature paper from our lab on groundbreaking genome editing tools unlocking new possibilities for precision medicine

Our new Nature Biotechnology paper "Activation of recombinases at specific DNA loci by zinc-finger domain insertions” has just been published! It describes a newly developed method combining the…

Read More

Wirtschaftswoche “Start-up of the week”

Newspaper "Wirtschaftswoche" votes Seamless Therapeutics as "Start-up of the week". In this newspaper feature, start-ups pitch their business idea. This time it's Seamless Therapeutics and expert…

Read More

New publication from our lab

Check out our brand-new publication on "Quantification of evolved DNA-editing enzymes at scale with DEQSeq". Congratulations to everyone involved!  

Read More

Frank Buchholz honoured for his commitment to transfer innovation from research to industry

On 6 September 2023, UNIPRENEURS honoured 20 outstanding professors & founders for their achievements in transfer of innovation who had been selected from 700 nominations. Prof. Dr. Frank…

Read More

Frank Buchholz and Seamless Therapeutics GmbH on designer recombinases competing with CRISPR

In our latest news release, Frank Buchholz (TU Dresden) and Anne-Kristin Heninger (Seamless Therapeutics GmbH) look at how designer recombinases have become a strong competitor of CRISPR. Explaining…

Read More

Laborjournal on Seamless Therapeutics

In their news article in Laborjournal, the Dresden-based start-up Seamless Therapeutics reflects on programmable recombinases that operate independently of the cell's own DNA repair system and could…

Read More

Jenna Hoersten represented the Buchholz Lab at the 26th ASGCT Annual Meeting in Los Angeles

The American Society of Gene and Cell Therapy’s (ASGCT) Annual Meeting is considered the premier event for professionals in gene and cell therapy. Our PhD student Jenna participated at this year's…

Read More

New publication on tyrosine-type site-specific recombinases

Our new paper “Discovery and characterization of novel Cre-type tyrosine site-specific recombinases for advanced genome engineering” in collaboration with DKMS Life Science Lab has just been…

Read More

Frank Buchholz participating in open discussion on genetic research

Is there a gene for a bigger and more efficient brain? Can genome surgery soon free us from all diseases? Do my genes determine my character? During audience discussions, experts exchange views on…

Read More

The TU Dresden Spin-off Seamless Therapeutics Launches with $12.5M Seed Financing to Advance Transformative Gene Editing Platform Based on Programmable Precision Designer Recombinases in Dresden

Seed round co-led by Wellington Partners and Forbion, with additional non-dilutive financial support from the BMBF (GO-Bio funding) enables maturation of the proprietary platform and pipeline…

Read More

Frank Buchholz featured in DHMD podcast “You Ask We Explain”

A new episode of the podcast series “You Ask We Explain” by Deutsches Hygiene-Museum Dresden (DHMD) features Prof. Dr. Frank Buchholz. Titled “It’s all a question of genes. The chance of limitless…

Read More

Dresden Excellence Award for Dr. Felix Lansing

Dr Felix Lansing has won the Science Award of the City of Dresden in the doctoral category and was honoured for his dissertation work “Wie neuartige Gen-Skalpelle die Gen-Therapie revolutionieren –…

Read More

Shady Sayed wins Young Investigator Award

Our postdoc Shady Sayed is one of the winners of the Young Investigator Award of the 21st International AEK Cancer Congress. The Young Investigator Award in the amount of 500 EUR was awarded by the…

Read More

Shady Sayed representing the Buchholz Lab at the 21st International AEK Cancer Congress in Kassel

Shady Sayed’s abstract has been selected as an abstract short talk at the 21st International AEK Cancer Congress in Kassel from February 15 to 17, 2023. The abstract titled “Efficient Correction of…

Read More

Deutscher Studienpreis award ceremony for Felix Lansing in Berlin

For this groundbreaking contribution to finding treatment for more then 8,000 diseases  that can be traced back to gene defect, Felix Lansing was awarded second place in the Deutscher Studienpreis of…

Read More

Felix Lansing awarded Deutscher Studienpreis in Natural and Technical Sciences

Dr Felix Lansing has made a groundbreaking contribution to cell and gene therapy, for which he was awarded 2nd place in the Deutscher Studienpreis by the Körber Foundation. “In my dissertation,”…

Read More

New start-up company RecTech GmbH founded

RecTech GmbH is a brand new start-up focused on developing designer recombinases for precision genome editing. Supported by the BMBF GO-Bio programme, the lab of Frank Buchholz founded the company to…

Read More

Designer recombinase can precisely correct disease-relevant gene defect in severe form of hemophilia A

The research team led by Prof. Frank Buchholz at the Carl Gustav Carus Medical Faculty of the Technical University of Dresden has succeeded in developing an enzyme that can efficiently and…

Read More

Interview on communication in science with Prof. Dr. Frank Buchholz

On 18 January 2022, mdr Sachsen published a podcast on the topic “Is there a therapy for Long Covid?” in which Prof. Dr. Frank Buchholz comments on communication in science within and with the…

Read More

Prof. Frank Buchholz new Dean of Research at the Medical Faculty

As Dean of Research, Prof. Frank Buchholz will continue the previous work and set new priorities. The objective of the Office of the Dean of Research at the Medical Faculty of the TU Dresden is: - to…

Read More

German Alliance of Scientific Organisations: Call for more objectivity in crisis situations

The German Alliance of Scientific Organisations has taken a stand on the current reporting by the BILD newspaper in connection with the coronavirus pandemic by calling for more objectivity in crisis…

Read More

BMBF Cluster4Future SaxoCell® focusses on therapeutic options for previously incurable diseases

At the kick-off meeting on 16 November, the BMBF Future Cluster was launched with the vision of establishing an independent industry in Saxony that will focus on “living medicines”. Prof. Frank…

Read More

Frank Buchholz among this year’s Falling Walls finalists

Frank Buchholz has been selected as a finalist for the Falling Walls Science Breakthroughs of the Year 2021 in Life Sciences. The award recognizes ground-breaking work contributing towards solving…

Read More

Business Plan Competition – RecTech team from Dresden wins second place at Science4Life Venture Cup

The Dresden research team has developed a promising business concept to revolutionize molecular medicine based on a customized designer recombinase technology. This genome editing technology is…

Read More

Science4Life – The Dresden RecTech team has successfully participated in the competition again

The Dresden start-up project RecTech led by Prof. Frank Buchholz and Dr. Anne-Kristin Heninger emerged as one of the winners at the Science4Life TechSLAM on May 11, 2021. Within this competition, 20…

Read More

The tailored genome – How enzymes can help to cure hereditary diseases

The start-up project RecTech led by Prof. Frank Buchholz and Dr. Anne-Kristin Heninger has once again succeeded in scoring points in the prestigious Science4Life Venture Cup. This time, RecTech was…

Read More

Start-up RecTech is one of the winners of the 2021 Science4Life Venture Cup first phase

Within the business plan competition of the 2021 Science4Life Venture Cup, 97 applicants presented their innovative business ideas and 5 teams were awarded with a prize for the best business idea.…

Read More

Development of a powerful gene editing tool to correct a genomic inversion frequently found in Hemophilia A

Hemophilia A (HA) is the most commonly occurring inheritable deficiency of blood coagulation. Severely affected individuals suffer frequent spontaneous haemorrhaging, which can lead to chronic…

Read More